10-Q: InnovAge Reports Q3 2024 Results: Revenue Growth Offset by Increased Costs

InnovAge Holding Corp. reports a revenue increase for the third quarter of 2024, but faces challenges with rising operating expenses and ongoing regulatory scrutiny.

Summary

• InnovAge Holding Corp. reported a net loss of $5.9 million for the third quarter of 2024, compared to a net loss of $6.6 million in the same period last year.
• The company's revenue increased by 11.9% to $193.1 million, driven by growth in capitation revenue.
• Operating expenses also increased, with external provider costs rising by 11.3% and cost of care increasing by 9.5%.
• For the nine months ended March 31, 2024, the company's net loss was $19.6 million, compared to a net loss of $29.5 million in the same period last year.
• The company's revenue for the nine months ended March 31, 2024, was $564.5 million, an increase of 10.4% compared to the same period last year.
• The company served approximately 6,820 PACE participants as of March 31, 2024, and operated 19 PACE centers across six states.
• The company is working to remediate deficiencies identified in recent audits at its Sacramento and San Bernardino centers.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While revenue is growing and losses are decreasing, the company is facing significant challenges with rising costs, regulatory scrutiny, and legal proceedings. The sentiment is neutral to slightly negative due to the ongoing issues.

Positives

• Revenue increased by 11.9% in Q3 2024 and 10.4% for the nine months ended March 31, 2024, indicating strong growth in the business.
• The company's net loss improved for both the quarter and the nine-month period compared to the previous year.
• Adjusted EBITDA showed a significant improvement, reaching $13.6 million for the nine months ended March 31, 2024, compared to a loss in the same period last year.
• The company successfully acquired two PACE programs in California, expanding its presence in the state.
• The company has seen an 8.1% growth in census for the nine months ended March 31, 2024 compared to the same period last year.

Negatives

• Operating expenses, particularly external provider costs and cost of care, increased significantly, offsetting some of the revenue gains.
• The company is facing ongoing regulatory scrutiny, including audits at its Sacramento and San Bernardino centers, which could impact future growth.
• The company experienced a decrease in cash and cash equivalents of $73.1 million from June 30, 2023, primarily due to the acquisition of ConcertoCare PACE centers and timing of cash receipts.
• The company is experiencing delays in processing Medicaid applications and redeterminations, which could impact revenue recovery.

Risks

• The company faces risks related to its ability to effectively implement post-sanction remediation efforts and maintain regulatory compliance.
• The company is exposed to macroeconomic challenges, including inflation and labor shortages, which could increase operating costs.
• The company's financial performance is dependent on capitated arrangements with government payors, which are subject to change.
• The company is subject to ongoing legal proceedings, including civil investigative demands and stockholder lawsuits, which could have a material adverse effect on its business.
• The company's ability to expand via de novo centers is subject to regulatory approvals and audits.
• The company is facing increased competition for healthcare professionals, which could increase labor costs.
• The company's labor costs may increase due to unionization efforts at its Pennsylvania centers.

Future Outlook

The company expects to continue to experience elevated operating expenses for the remainder of fiscal 2024 due to macroeconomic conditions and increased costs of care. The company plans to continue investing in its centers, value-based care model, and sales and marketing organization to support long-term growth. The company is also working to remediate deficiencies identified in recent audits and expand its presence in new markets.

Management Comments

• The company's priority is to continue to remediate the deficiencies raised in audit processes and to implement post-sanction corrective actions.
• The company is working to fill critical personnel gaps at its centers, standardize the process of its Interdisciplinary Care Teams (IDTs), strengthen its home care network and reliability, and improve timelines of scheduling and coordinating care with providers outside its centers.
• The company believes that its cash and cash equivalents and its cash flows from operations, available funds, and access to financing sources will be sufficient to fund its operating and capital needs for the next 12 months and beyond.

Industry Context

The healthcare sector is experiencing increased demand due to an aging population and a greater focus on health and wellness. The company is facing challenges related to labor shortages and inflation, which are impacting the entire industry. The company's focus on providing all-inclusive care to frail, high-cost, dual-eligible seniors positions it to benefit from the growing demand for senior care services.

Comparison to Industry Standards

• InnovAge's PACE model is designed to manage a higher acuity population than Medicare Advantage (MA) programs, resulting in larger payments per participant.
• The company's average risk adjustment factor (RAF) score of 2.47 as of March 31, 2024, indicates a higher level of medical complexity compared to typical MA participants.
• The company's participant satisfaction rating of 86% as of September 30, 2023, suggests a strong level of participant satisfaction compared to industry averages.
• The company's average participant tenure of 3.1 years as of March 31, 2024, indicates a high level of participant retention compared to industry averages.
• The company's low levels of controllable disenrollment, averaging 6.0% annually over the last three fiscal years, suggest a strong level of participant retention compared to industry averages.
• The company's Center-level Contribution Margin of 16.9% for the nine months ended March 31, 2024, indicates a strong level of profitability compared to industry averages.

Legal Proceedings

• The company is involved in a civil investigative demand from the Attorney General for the State of Colorado regarding Medicaid billing, patient services, and referrals.
• The company is also subject to a civil investigative demand from the Department of Justice regarding audits, billing, orders tracking, and quality and timeliness of patient services.
• The company is named as a defendant in a putative class action complaint filed in the District Court for the District of Colorado on behalf of individuals who purchased or acquired shares of the company's common stock.
• The company is also subject to a derivative lawsuit in the Delaware Court of Chancery asserting claims for breach of fiduciary duty against certain of the company's current and former officers and directors.

Related Party Transactions

• The general partner of Pinewood Lodge, LLP, a subsidiary of the company, funds operating deficits and shortfalls of PWD in the form of a loan.
• The general partner is also paid an administration fee of $35,000 per year.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance, ongoing legal proceedings, and regulatory scrutiny.
• Employees are impacted by the company's efforts to address labor shortages and unionization efforts.
• Participants are impacted by the company's efforts to maintain high-quality care and regulatory compliance.
• Government payors are impacted by the company's ability to manage costs and comply with regulations.

Next Steps

• The company will continue to remediate deficiencies identified in recent audits.
• The company will continue to implement post-sanction corrective actions.
• The company will continue to invest in its centers, value-based care model, and sales and marketing organization.
• The company will continue to evaluate the impact of California Senate Bill No. 525 on its business.
• The company will continue to negotiate collective bargaining agreements with the unionized nurses at its Pennsylvania centers.

Key Dates

Keywords

PACE, healthcare, capitation, Medicaid, Medicare, senior care, regulatory compliance, audits, operating expenses, revenue growth, EBITDA, acquisition